This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).
Study Type
OBSERVATIONAL
Enrollment
200
No drug intervention or tissue sampling will be included in this study.
Hunan Province Tumor Hospital
Changsha, Hunan, China
RECRUITINGProgression-Free-Survival
From the time the first patient included in the observational analysis received treatment until disease progression, death due to various causes or censored at the date of last contact
Time frame: Assessed up to around 4.5 years
Overall Survival
From the time the first patient included in the observational analysis received treatment until death due to various causes or censored at the date of last contact
Time frame: Assessed up to around 4.5 years
Clinical relevance between genomic profiling and progression-free-survival
Kaplan-Meier analysis for progression-free survival, utilizing data from various genetic testing methods including NGS and FISH, to evaluate the impact of different genetic alterations.
Time frame: Assessed up to around 4.5 years
Clinical relevance between genomic profiling and overall survival
Kaplan-Meier analysis for overall survival, utilizing data from various genetic testing methods including NGS and FISH, to evaluate the impact of different genetic alterations.
Time frame: Assessed up to around 4.5 years
ORR
Proportion of patients whose tumor volume shrinks to a pre-specified value (usually 30%) and who are able to maintain the minimum timeframe requirements.
Time frame: Assessed up to around 4.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.